Medicis Pharmaceutical (MRX) Stock Price, News & Analysis

Company Overview

Medicis Pharmaceutical Corporation (Medicis) together with its wholly owned subsidiaries is an independent specialty pharmaceutical company engaged in the development and marketing of products for the treatment of dermatological and aesthetic conditions in the United States and Canada. Medicis offers a range of products addressing various conditions or aesthetic improvements, including facial wrinkles. Its brands are DYSPORT (abobotulinumtoxinA) 300 Units for Injection, PERLANE Injectable Gel, RESTYLANE Injectable Gel, SOLODYN (minocycline HCl, USP) Extended Release Tablets, VANOS (fluocinonide) Cream 0.1%, ZIANA (clindamycin phosphate 1.2% and tretinoin 0.025%) Gel and ZYCLARA (imiquimod) Cream 3.75% and 2.5%. As of December 31, 2011, it offered 27 branded products. On December 2, 2011, it acquired Graceway Pharmaceuticals, LLC (Graceway). On November 1, 2011, Medicis sold Medicis Technologies Corporation, formerly LipoSonix, Inc., to Solta Medical, Inc. (Solta).

Key Stats

• Today's Range: $28.34 to $29.10
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 730,765 shs
• Average Volume: 663,332 shs
• Market Capitalization: $1.99 billion
• P/E Ratio: N/A
• Dividend Yield: 1.98%
• Price Target: $30.71
• Consensus Rating: Buy

Medicis Pharmaceutical Stock Analysis - MarketRank™

Medicis Pharmaceutical scored higher than 5% of companies evaluated by MarketBeat, and ranked 956th out of 958 stocks in the finance sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.5 / 5
• Analyst Rating: Buy

Consensus Rating

Medicis Pharmaceutical has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Medicis Pharmaceutical has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: -0.34%

Earnings Growth

Earnings for Medicis Pharmaceutical are expected to decrease by -0.34% in the coming year, from $2.93 to $2.92 per share.

Price to Book Value per Share Ratio

Medicis Pharmaceutical has a P/B Ratio of 2.08. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for MRX.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

Medicis Pharmaceutical pays a meaningful dividend of 1.97%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Medicis Pharmaceutical does not have a long track record of dividend growth.

Dividend Sustainability

Based on earnings estimates, Medicis Pharmaceutical will have a dividend payout ratio of 19.18% next year. This indicates that Medicis Pharmaceutical will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for MRX.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

10 people have searched for MRX on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Medicis Pharmaceutical insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.79% of the stock of Medicis Pharmaceutical is held by insiders.

MRX Stock Analysis - Frequently Asked Questions

How were Medicis Pharmaceutical's earnings last quarter?

Medicis Pharmaceutical Corp (NYSE:MRX) announced its earnings results on Thursday, November, 7th. The healthcare company reported $0.76 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.68 by $0.08. The company's revenue was up 31.9% compared to the same quarter last year.

When did Medicis Pharmaceutical IPO?

Medicis Pharmaceutical (MRX) raised $292 million in an initial public offering on Thursday, April 25th 2024. The company issued 15,384,615 shares at a price of $19.00 per share.

When did Medicis Pharmaceutical's lock-up period expire?

Medicis Pharmaceutical's lock-up period expired on Tuesday, October 22nd. Medicis Pharmaceutical had issued 15,384,615 shares in its IPO on April 25th. The total size of the offering was $292,307,685 based on an initial share price of $19.00. Shares of the company owned by major shareholders and company insiders are now eligible to be traded as a result of the end of the lock-up period.

What other stocks do shareholders of Medicis Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Medicis Pharmaceutical investors own include Tesla (TSLA), JPMorgan Chase & Co. (JPM), NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Netflix (NFLX) and Home Depot (HD).

Company Calendar

• Ex-Dividend for 9/16 Dividend: 8/30/2024
• Dividend Payable: 9/16/2024
• Last Earnings: 11/07/2024
• Today: 11/16/2024
• Ex-Dividend for 12/10 Dividend: 11/25/2024
• Dividend Payable: 12/10/2024
• Fiscal Year End: 12/31/2024
• Next Earnings (Estimated): 4/28/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Finance
• Industry: Security & commodity brokers, dealers, exchanges & services
• Sub-Industry: N/A
• Current Symbol: NYSE:MRX
• CUSIP: N/A
• CIK: 859368
• Web: www.Medicis.com
• Phone: +1-212-5992000
• Fax: N/A
• Employees: 2,074
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $30.71
• High Stock Price Target: $34.00
• Low Stock Price Target: $24.00
• Potential Upside/Downside: +8.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 7 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 1.18
• Current Ratio: 1.04
• Quick Ratio: 1.08

Sales & Book Value

• Annual Sales: $1.24 billion
• Price / Sales: 1.60
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $13.65 per share
• Price / Book: 2.08

Miscellaneous

• Outstanding Shares: 70,290,000
• Free Float: 67,627,000
• Market Cap: $1.99 billion
• Optionable: Optionable
• Beta: N/A